<DOC>
	<DOCNO>NCT02312960</DOCNO>
	<brief_summary>Patients follow study prior treatment BAY 88-8223 / Radium-223 dichloride / Xofigo .</brief_summary>
	<brief_title>Radium-223 Dichloride Long-term Follow-up Program</brief_title>
	<detailed_description>This long-term follow study enroll subject transfer select interventional , company sponsor trial radium-223 dichloride ( feeder trial ) . The primary objective define long term safety profile radium-223 dichloride ( 7 year last dose radium-223 dichloride ) ; assess incidence leukemia , myelodysplastic syndrome , aplastic anemia , primary bone cancer new primary malignancy ; , subject receive cytotoxic chemotherapy , assess incidence febrile neutropenia hemorrhage chemotherapy treatment 6 month thereafter frequency base local clinical practice .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Succinylcholine</mesh_term>
	<mesh_term>Radium Ra 223 dichloride</mesh_term>
	<criteria>Subject previously enrol select company sponsor feeder trial , receive least 1 dose radium 223 dichloride placebo feeder trial Not applicable follow study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>